275 related articles for article (PubMed ID: 33795387)
1. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
[TBL] [Abstract][Full Text] [Related]
5. Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow.
Manenq C; Lesesve JF; Dreumont N; Massin F; Salignac S; Mansuy L; Chastagner P; Latger-Cannard V; Broséus J
Int J Lab Hematol; 2020 Feb; 42(1):52-60. PubMed ID: 31821742
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry as a diagnostic tool in neuroblastoma.
Furlanetto G; Spagnol F; Alegretti AP; Farias MG; Soares VJ; Daudt LE; Loss JF; Scroferneker ML; Michalowski MB
J Immunol Methods; 2021 Nov; 498():113135. PubMed ID: 34478717
[TBL] [Abstract][Full Text] [Related]
7. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
[TBL] [Abstract][Full Text] [Related]
8. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
[TBL] [Abstract][Full Text] [Related]
9. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of Multicolor Flow Cytometry and Immunohistochemistry for the Detection of Disseminated Tumor Cells.
Szánthó E; Kárai B; Ivády G; Bedekovics J; Szegedi I; Petrás M; Ujj G; Ujfalusi A; Kiss C; Kappelmayer J; Hevessy Z
Appl Immunohistochem Mol Morphol; 2018; 26(5):305-315. PubMed ID: 28426528
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of bone marrow lesions in children with neuroblastoma detected by flow cytometry].
Popov AM; Shorikov EV; Verzhditskaia TIu; Tsaur GA; Druĭ AE; Solodovnikov AG; Savel'ev LI; Fechina LG
Vopr Onkol; 2014; 60(4):469-75. PubMed ID: 25552066
[TBL] [Abstract][Full Text] [Related]
12. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
13. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
14. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
15. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.
Eichholz T; Heubach F; Arendt AM; Seitz C; Brecht IB; Ebinger M; Flaadt T; Süsskind D; Richter L; Hülsenbeck I; Zerweck L; Göricke S; Paulsen F; Dombrowski F; Flotho C; Schönberger S; Ketteler P; Schulte J; Lang P
Cancer Immunol Immunother; 2024 Jan; 73(1):19. PubMed ID: 38240863
[TBL] [Abstract][Full Text] [Related]
18. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
19. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
[TBL] [Abstract][Full Text] [Related]
20. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
